A transapical transcatheter mitral valve repair system was linked to extensive reduction in mitral regurgitation at 2 years in patients ineligible for surgery, researchers reported at TVT: The Structural Heart Summit. Martin B. Leon, MD, FACC, professor of medicine at Columbia University Irving Medical Center, director of Columbia Interventional Cardiovascular Care and director of the
Results Suggest CardiAMP Cell Therapy May Have Ability to Restore and Maintain Heart Function to Previously Non-Functioning Areas of the Heart Up to Two Years After Treatment
TUESDAY, Feb. 7, 2023 (HealthDay News) Treatment with a moderately accelerated personalized backup pacing rate (myPACE) is beneficial for patients with stage B and C heart failure with preserved
A study challenges the dogma of beta-blockers for HF with preserved ejection fraction. For now, the strategy might only be for HFpEF patients already with pacemakers.